Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPACE-HIV
NCT07144293Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in frailty syndrome, sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2025; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT07144293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144293.